<DOC>
	<DOCNO>NCT00006003</DOCNO>
	<brief_summary>SU5416 may stop growth malignant melanoma stop blood flow tumor . Phase II trial study effectiveness SU5416 treat patient metastatic melanoma previously treat</brief_summary>
	<brief_title>SU5416 Treating Patients With Metastatic Melanoma That Has Been Previously Treated</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine objective response rate stabilization disease rate patient previously treat metastatic melanoma treat SU5416 . II . Determine toxicity SU5416 patient population . III . Determine median overall survival time progression patient receive treatment . OUTLINE : This multicenter study . Patients receive SU5416 IV 60 minute twice weekly 4 week . Treatment continue minimum 2 course absence unacceptable toxicity disease progression . Patients follow weekly 4 week . PROJECTED ACCRUAL : A total 14-35 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<criteria>Histologically confirm melanoma document metastatic disease In transit metastasis allow Lesion accessible biopsy Measurable disease Greater 20 mm conventional technique ORgreater 10 mm spiral CT Documented progressive disease radiologic study physical examination Known history CNS metastasis treatment , neurologicallystable , require intravenous antibiotic anticonvulsant eligibleprovided oral steroid require brain scan ( CT MRI ) showsabsence active residual disease If neurologic sign symptom suggestive CNS metastasis , negative brain scan require Performance status WHO 02 At least 12 week WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL Transaminases great 2.5 time upper limit normal Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min No uncompensated coronary artery disease No history myocardial infarction severe/unstable angina within past 6 month No severe peripheral vascular disease associate diabetes mellitus No deep venous arterial thrombosis within past 3 month No pulmonary embolism within past 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant uncontrolled underlying medical psychiatric illness No serious active infection No malignancy within past 5 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix No history severe allergic anaphylactic reaction paclitaxel docetaxel No concurrent chemotherapy No concurrent investigational antineoplastic drug See Disease Characteristics No prior radiotherapy site measurable disease At least 4 week since prior radiotherapy recover No concurrent radiotherapy No great 1 prior therapy metastatic disease At least 4 week since prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>